Related Experiment Video

Updated: Jan 19, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.2K

Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors

Dan Wang1,2,3, Li Yang1,2,3, Weina Yu1,2,3

  • 1Biotherapy Center, The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , P.R. China.

Expert Opinion on Investigational Drugs
|September 28, 2019
PubMed

Insights

Fibroblast growth factor receptor 2 (FGFR2) is a key target in cancer therapy. Developing specific FGFR2 blockers and improving patient selection are crucial for effective treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase receptor implicated in numerous human solid tumors.
  • FGFR2 dysregulation and overexpression correlate with tumor progression, establishing it as a significant therapeutic target in oncology.

Purpose of the Study:

  • This review critically examines the regulatory mechanisms and functional roles of FGFR2 in cancer development.
  • It evaluates the potential of FGFR2 as a therapeutic target for various human cancers.

Main Methods:

  • The review synthesizes current research on FGFR2's involvement in cancer.
  • It analyzes emerging targeted therapies, including multi-target tyrosine kinase inhibitors (TKIs), pan-FGFR TKIs, and FGFR2 monoclonal antibodies.

Main Results:

  • While FGFR2 is a promising target, highly specific blockers are still under development.
  • Resistance to current FGFR2-targeted therapies presents a significant clinical challenge.

Conclusions:

  • Improved patient stratification strategies are essential to enhance the efficacy of FGFR2-targeted therapies.
  • Combination therapy approaches are considered the most promising strategy for patients with FGFR2 alterations.
Keywords:
FGFR-target TKIsFibroblast growth factor receptor 2 (FGFR2)antibodymulti-target tyrosine kinase inhibitors (TKIs)solid tumor

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.1K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
453